Table 1.

Patient information pertaining to leukemia diagnosis and treatment

	Patient A	Patient B	Patient C	Patient D	Patient E
Diagnosis	MLL‐R ALL	MLL‐R ALL	MLL‐R ALL	MLL nonrearranged ALL	MLL nonrearranged ALL
Age at diagnosis	5 month old	5 month old	7 month old	8 month old	11 month old
Treatment	COG AALL0631a	COG AALL0631b	COG AALL0631b	CCG 1953	CCG P9407
	No Lestaurtanib	No Lestaurtanib	No Lestaurtanib
Treatment course complications	Bacterial and fungal infections	Bacterial and viral infections, extensive thrombi involving upper venous system, enteritis	None	Bacterial and viral infections	Bacterial infections, chronic rhinorrhea/sinusitis
Age at end of chemotherapy treatment	29 month old	29 month old	31 month old	33 month old	24 month old
Course after chemotherapy treatment	CMV viremia and cystitis, Clostridium difficile colitis, Mycobacterium chelonae cellulitis	Clostridium difficile colitis, oral herpes simplex virus, norovirus, bocavirus, rhinovirus, and HHV‐6 viremia, Enterobacter cloacae cystitis, pneumatosis intestinalis	Mycobacterium chelonae abscesses, parainfluenza‐3, coronavirus, CMV retinitis, Candida esophagitis	Pulmonary aspergillus, Pseudomonas sepsis	Parainfluenza type 3 sinusitis, HHV‐6 viremia, and encephalitis
Age immunodeficiency confirmed	31 month old	31 month old	44 month old	36 month old	31 month old
Therapy after ALL treatment	None	Interleukin‐7	HSCT	None	HSCT
Current age or age at death	31 month old (deceased)	35 month old (deceased)	50 month old (deceased)	37 month old (deceased)	8‐year‐old (alive)
Autopsy results	Disseminated aspergillosis; severe thymic involution; lymphoid depletion	Diffuse bronchopneumonia; severe thymic involution, lymphoid depletion	Diffuse alveolar damage	Autopsy not performed	Not applicable

ALL, acute Lymphoblastic leukemia; MLL, mixed lineage leukemia gene; MLL‐R, MLL rearranged; COG, Children's Oncology Group; CCG, Children's Cancer Study Group; HSCT, hematopoietic stem cell transplant. CMV, cytomegalovirus; HHV‐6, human herpesvirus 6.

^aTreated before induction amendments.

^bTreated after induction amendments (elimination of cyclophosphamide 1 g/m²).

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.